JPH0480887B2 - - Google Patents
Info
- Publication number
- JPH0480887B2 JPH0480887B2 JP59010858A JP1085884A JPH0480887B2 JP H0480887 B2 JPH0480887 B2 JP H0480887B2 JP 59010858 A JP59010858 A JP 59010858A JP 1085884 A JP1085884 A JP 1085884A JP H0480887 B2 JPH0480887 B2 JP H0480887B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- ifn
- solution
- human ifn
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 31
- 239000007864 aqueous solution Substances 0.000 claims description 30
- 108010074328 Interferon-gamma Proteins 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000003398 denaturant Substances 0.000 claims description 11
- 108010050904 Interferons Proteins 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- 102000008070 Interferon-gamma Human genes 0.000 claims description 5
- 239000000539 dimer Substances 0.000 claims description 5
- 229940044627 gamma-interferon Drugs 0.000 claims description 4
- 239000013631 noncovalent dimer Substances 0.000 claims description 2
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 48
- 235000018102 proteins Nutrition 0.000 description 48
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 102100037850 Interferon gamma Human genes 0.000 description 24
- 238000002523 gelfiltration Methods 0.000 description 20
- 238000010828 elution Methods 0.000 description 18
- 239000000178 monomer Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 229960000789 guanidine hydrochloride Drugs 0.000 description 13
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 239000000872 buffer Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 150000003464 sulfur compounds Chemical class 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 108010024636 Glutathione Proteins 0.000 description 8
- 229920001213 Polysorbate 20 Polymers 0.000 description 8
- 239000008351 acetate buffer Substances 0.000 description 8
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 229960001305 cysteine hydrochloride Drugs 0.000 description 5
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010038061 Chymotrypsinogen Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007863 gel particle Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- REYLLNRLWCBKCM-YFKPBYRVSA-N (2s)-2-acetamido-4-sulfanylbutanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCS REYLLNRLWCBKCM-YFKPBYRVSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 1
- 229930195710 D‐cysteine Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940081090 cefa Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59010858A JPS60155137A (ja) | 1984-01-23 | 1984-01-23 | 高濃度ヒトγ型インタ−フエロン水溶液の製造法 |
| IL8574093A IL74093A0 (en) | 1984-01-23 | 1985-01-18 | Stable composition of gamma-interferon |
| IL74094A IL74094A0 (en) | 1984-01-23 | 1985-01-18 | Highly solubilised protein and production thereof |
| EP85100549A EP0150066A3 (en) | 1984-01-23 | 1985-01-19 | Highly solubilized protein and production thereof |
| GR850157A GR850157B (enrdf_load_html_response) | 1984-01-23 | 1985-01-21 | |
| KR1019850000357A KR850005456A (ko) | 1984-01-23 | 1985-01-22 | 고농도 단백질의 제조방법 |
| ZA85496A ZA85496B (en) | 1984-01-23 | 1985-01-22 | Highly solubilized protein and production thereof |
| PT79853A PT79853B (en) | 1984-01-23 | 1985-01-22 | Process for the preparation of an highly solubilized protein |
| NZ210896A NZ210896A (en) | 1984-01-23 | 1985-01-22 | Producing highly concentrated human gamma-interferon aqueous solutions |
| ES539736A ES8702441A1 (es) | 1984-01-23 | 1985-01-22 | Un metodo de producir una solucion acuosa, muy concentrada, de gamma-interferon de humano |
| DK28885A DK28885A (da) | 1984-01-23 | 1985-01-22 | Hoejkoncentreret vandig human gamma-interferonoploesning samt fremgangsmaade til fremstilling deraf |
| CA000472599A CA1255220A (en) | 1984-01-23 | 1985-01-22 | Highly solubilized protein and production thereof |
| AU38017/85A AU3801785A (en) | 1984-01-23 | 1985-01-23 | Concentrated solutions of human gamma interferon |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59010858A JPS60155137A (ja) | 1984-01-23 | 1984-01-23 | 高濃度ヒトγ型インタ−フエロン水溶液の製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60155137A JPS60155137A (ja) | 1985-08-15 |
| JPH0480887B2 true JPH0480887B2 (enrdf_load_html_response) | 1992-12-21 |
Family
ID=11762050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59010858A Granted JPS60155137A (ja) | 1984-01-23 | 1984-01-23 | 高濃度ヒトγ型インタ−フエロン水溶液の製造法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS60155137A (enrdf_load_html_response) |
| ZA (1) | ZA85496B (enrdf_load_html_response) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3618817A1 (de) * | 1986-06-04 | 1987-12-10 | Behringwerke Ag | Verfahren zur gewinnung aktiver proteine aus einer biologisch inaktiven form |
| JP2537935B2 (ja) * | 1987-12-29 | 1996-09-25 | 住友製薬株式会社 | 生理活性物質の農縮・脱塩方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5598118A (en) * | 1979-01-18 | 1980-07-25 | Hayashibara Takeshi | Preparation of type-2 interferon and drug containing the same |
| GR79124B (enrdf_load_html_response) * | 1982-12-22 | 1984-10-02 | Genentech Inc |
-
1984
- 1984-01-23 JP JP59010858A patent/JPS60155137A/ja active Granted
-
1985
- 1985-01-22 ZA ZA85496A patent/ZA85496B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60155137A (ja) | 1985-08-15 |
| ZA85496B (en) | 1986-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arora et al. | Method for increasing the yield of properly folded recombinant human gamma interferon from inclusion bodies | |
| Van Snick et al. | The binding of human lactoferrin to mouse peritoneal cells. | |
| Yonemasu et al. | Chemical studies on Clq; a modulator of immunoglobulin biology | |
| Törmä et al. | Purification and characterization of human leukocyte interferon components. | |
| US5196323A (en) | Process for preparing and purifying alpha-interferon | |
| JPS63169995A (ja) | β−インターフェロンの回収及び精製方法 | |
| JPH0428279B2 (enrdf_load_html_response) | ||
| CA1211711A (en) | Removal of impurities from human leukocyte interferon preparations | |
| EP0168008A2 (en) | Stable composition of gamma-interferon | |
| JPH0480887B2 (enrdf_load_html_response) | ||
| KR940010024B1 (ko) | α-인터페론의 제조 및 정제 방법 | |
| AU783571B2 (en) | Method of monomerizing human serum albumin polymers | |
| Moschera et al. | [25] Purification of recombinant human fibroblast interferon produced in Escherichia coli | |
| EP0150066A2 (en) | Highly solubilized protein and production thereof | |
| Burton et al. | Progesterone-binding globulin from the serum of pregnant guinea pigs, a polydisperse glycoprotein | |
| JPH08116985A (ja) | 遺伝子操作に由来するヒト血清アルブミンの精製方法 | |
| US4723000A (en) | Human interferon gamma and interleukin-2 | |
| WO1992014832A1 (en) | Processes for purifying human bcdf | |
| JPH064680B2 (ja) | 高濃度ヒトγ型インターフェロンフラグメント水溶液の製造法 | |
| Havell et al. | Two molecular weight species of murine gamma interferon | |
| KR900008571B1 (ko) | 효모에서 발현된 인체 γ-인터페론의 정제방법 | |
| Langer et al. | [34] Procedure for reduction and reoxidation of human leukocyte interferon | |
| Ejima et al. | Biotech applications of arginine | |
| Civas et al. | Purification and carbohydrate structure of natural murine interferon‐β | |
| JPS60155136A (ja) | γ型インタ−フエロン組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |